New Zealand Professional Investment Services Firm, Forsyth Barr

Forsyth Barr

New Zealand Professional Investment Services Firm

We are proud to be a New Zealand owned firm, with 21 offices throughout the country and over 300 employees. We assist personal, institutional and corporate clients providing a full range of investment services.

Forsyth Barr is a foundation New Zealand Exchange firm (NZX) and accredited market participant. We have been confirmed by the Financial Markets Authority as a Qualifying Financial Entity (QFE).

Research is the cornerstone of our advice. We have one of New Zealand's leading teams of analysts. Our global affiliations ensure comprehensive research coverage of all major investment markets.

Thematic (Sector/Industry)

<ul><li>The aged care sector is showing signs of stability with unit and sales pricing holding steady despite Ryman Healthcare's selective price cuts.</li><li>Oceania Healthcare is rated OUTPERFORM due to its resilient demand focus and potential for debt reduction through inventory sell down.</li><li>The New Zealand housing market shows signs of recovery, with sales improving and a stable period for unit price buffers expected over the medium term.</li></ul>

The aged care sector is showing signs of stability with unit and sales pricing holding steady despite Ryman Healthcare's selective price cuts.Oceania Healthcare is rated OUTPERFORM due to its resilient demand focus and potential for debt reduction through inventory sell down.The New Zealand housing market shows signs of recovery, with sales improving and a stable period for unit price buffers expected over the medium term.

Aged Care Sector - Montgomerie-Ibbotson Aged Care Pricing Index

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>Ono Pharmaceutical received FDA approval for Romvimza for the treatment of symptomatic tenosynovial giant cell tumor. Shionogi obtains domestic approval for digital therapeutic app, Endeavorride for ADHD.</li>
<li>Samsung Biologics received FDA and European Commission approval for Prolia biosimilar. Celltrion received European approval for Prolia and Eylea biosimilars. Cosette Pharmaceuticals is acquiring Mayne Pharma for A$7.40 per share.</li>
<li>CSPC Pharmaceutical granted an exclusive license to Radiance Biopharma to develop and commercialize antibody drug conjugates SYS6005 in selected geographies. Cipla received FDA approval for anti-cancer drug Nilotinib capsules.</li>
</ul>


Ono Pharmaceutical received FDA approval for Romvimza for the treatment of symptomatic tenosynovial giant cell tumor. Shionogi obtains domestic approval for digital therapeutic app, Endeavorride for ADHD.
Samsung Biologics received FDA and European Commission approval for Prolia biosimilar. Celltrion received European approval for Prolia and Eylea biosimilars. Cosette Pharmaceuticals is acquiring Mayne Pharma for A$7.40 per share.
CSPC Pharmaceutical granted an exclusive license to Radiance Biopharma to develop and commercialize antibody drug conjugates SYS6005 in selected geographies. Cipla received FDA approval for anti-cancer drug Nilotinib capsules.


APAC Healthcare Weekly (Feb 23)- Ono Pharma, Shionogi, Samsung Biologics, Celltrion, CSPC, Mayne

<div>
<div>
<div>
<div>
<ul>
<li>It takes approximately 15 years for a retirement village to be built and reach cash flow maturity, with an additional several decades of operational activity to follow.</li>
<li>The Aged Care sector operates on a time scale, where impacts from climate change are highly relevant.</li>
<li>In addition, the elderly are at the centre of the business model, some of the most vulnerable members of society. </li>
</ul>
</div>
</div>
</div>
</div>






It takes approximately 15 years for a retirement village to be built and reach cash flow maturity, with an additional several decades of operational activity to follow.
The Aged Care sector operates on a time scale, where impacts from climate change are highly relevant.
In addition, the elderly are at the centre of the business model, some of the most vulnerable members of society. 






<ul><li>On the face of it, little has changed in the aged care and NZ housing markets over the past six months.</li><li>House/unit prices are broadly flat and turnover remains a challenge.</li><li>But that hasn't stopped the aged care operators continuing to report record high sales numbers. </li></ul>

On the face of it, little has changed in the aged care and NZ housing markets over the past six months.House/unit prices are broadly flat and turnover remains a challenge.But that hasn't stopped the aged care operators continuing to report record high sales numbers. 

<ul><li>The proposed acquisition of Arvida Group (ARV) by Stonepeak Alps BidCo injected meaningful optimism into the listed aged care sector.</li><li>And rightly so. The aged care sector is suffering from a combination of (1) a lack of confidence in the business model driven by years of weak cash generation; (2) concerns around house prices and interest rates; and (3) an overly negative outlook on care profitability.</li><li>Whilst all issues are understandable, we view them as largely backward looking. </li></ul>

The proposed acquisition of Arvida Group (ARV) by Stonepeak Alps BidCo injected meaningful optimism into the listed aged care sector.And rightly so. The aged care sector is suffering from a combination of (1) a lack of confidence in the business model driven by years of weak cash generation; (2) concerns around house prices and interest rates; and (3) an overly negative outlook on care profitability.Whilst all issues are understandable, we view them as largely backward looking. 

Aged Care Sector - M&A Arrives to Aged Care

New Zealand

Summerset Group Holdings Ltd. is a profit-oriented entity and develops, owns and operates integrated retirement villages, rest homes and hospitals for the elderly within New Zealand.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Summerset Group Holdings (SUM NZ)

Aged Care Sector - Montgomerie-Ibbotson Aged Care Pricing Index

The aged care sector is showing signs of stability with unit and sales pricing holding steady despite Ryman Healthcare's selective price cuts.

Forsyth Barr

APAC Healthcare Weekly (Feb 23)- Ono Pharma, Shionogi, Samsung Biologics, Celltrion, CSPC, Mayne

APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...

Tina Banerjee

Aged Care Sector

It takes approximately 15 years for a retirement village to be built and reach cash flow maturity, with an additional several decades of...

Forsyth Barr

Aged Care Sector - Montgomerie-Ibbotson Aged Care Pricing Index

vOn the face of it, little has changed in the aged care and NZ housing markets over the past six months. House/unit prices are broadly flat and...

Forsyth Barr

Aged Care Sector - M&A Arrives to Aged Care

The proposed acquisition of Arvida Group (ARV) by Stonepeak Alps BidCo injected meaningful optimism into the listed aged care sector.

Forsyth Barr

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)